2026-06-27 · 2026-06 / week-4
Absci Prices the Lilly Halo, Not $215K Quarterly Revenue
Absci Prices the Lilly Halo, Not $215K Quarterly Revenue
Summary: Absci Corporation (NASDAQ: ABSI) trades at $10.95 with a $1.85B post-offering market cap, 48% above the $7.41 price at which Jefferies, JP Morgan, TD Securities, and Guggenheim just sold 13.5M shares two days ago. The market is pricing Eli Lilly's $40M participation as a clinical validation event. The filings describe a company with $215,000 in quarterly revenue, $30.8M in quarterly operating losses, a $400M dilution shelf, and no efficacy data until the second half of 2026.
Why This Is the Best Opportunity Right Now
The U.S. short screen surfaced three candidates from SEC EDGAR filings in the past week: MicroVision (MVIS) with a $150M ATM amendment at $0.30/share, Nexentis Technologies (NXTS) with a 424B5 filing at $4.80, and Absci (ABSI) with a $100M follow-on priced at $7.41 on June 24. ABSI is the strongest short because it combines the freshest catalyst (an offering priced just two trading days ago), the widest gap between market price and filing-implied value (48% above the underwriter-set price), and the most asymmetric downside (a preclinical-to-Phase 1 biotech with near-zero revenue valued at $1.85B). The $7.41 offering price is a mechanical ceiling set by four tier-one underwriters who spent weeks diligence-ing the company. The market has decided it knows better than Jefferies and JP Morgan, two days later, on the basis of a press release containing safety data from 32 healthy volunteers.
Opportunity Ranking
| Rank | Idea | Discovery Lane | Why It May Be Best Now | Evidence Freshness | Catalyst Window | Near-Term >5% Move Case | Asymmetry | Main Reason to Reject |
|---|---|---|---|---|---|---|---|---|
| 1 | Absci (ABSI) short | U.S. equity / follow-on overhang / biotech | $100M offering at $7.41 on June 24; stock 48% above offering price; $215K revenue, $1.85B market cap | Filing June 24, 2026; price June 26, 2026 | Active now: shelf + offering overhang | Reversion toward $7.41 offering price = 32% downside; break below $7.41 toward $5.16 (1-month low) = 53% downside | 32-53% downside to offering price or 1-month low; 20% upside risk to $13 if momentum continues | Squeeze risk from high volume; binary biotech catalyst (PoC data H2 2026) |
| 2 | MicroVision (MVIS) short | U.S. equity / ATM dilution / zero-revenue tech | $150M ATM amended June 12; stock at $0.30; zero revenue, $25M/Q loss | Filing June 24, 2026; price June 26, 2026 | Active: ATM deploying | ATM selling pressure at $0.30; dilution to $0.20 = 33% downside | 33-50% downside if ATM deploys; 50%+ upside risk on meme/squeeze | Already at $0.30, less room; large share count (331M) limits squeeze but also limits downside per share |
| 3 | Nexentis (NXTS) short | U.S. equity / micro-cap / 424B5 filing | 424B5 filed June 24; $4.80 stock, $6.6M Q1 loss, $4.3M cash | Filing June 24, 2026; price June 26, 2026 | Active: offering deploying | Dilution at $4.80; cash burn $6.6M/Q with $4.3M cash | 40-60% downside if offering prices below market | Extremely illiquid (20-day avg vol 3.9M but $4.80 stock on tiny float); borrow likely unavailable |
Selected opportunity: Absci Corporation (ABSI) short
Why this one now: ABSI offers the cleanest price-positioning-catalyst disagreement in the U.S. short screen. The offering price of $7.41, set by four investment banks on June 24, is a filing-verifiable anchor. The stock at $10.95 is 48% above that anchor two trading days later. The $400M shelf registration means the company has pre-registered another $300M of equity issuance capacity. The Phase 1 interim data released the same day as the offering contained safety and pharmacokinetic data only: no efficacy, no hair count results, no proof-of-concept. The market surged 36% on "positive" safety data from 32 healthy volunteers.
Why it can jump or dump >5% soon: ABSI has already moved 36% in one session (June 24) and another 7% on June 26. The offering settled shares at $7.41. The stock trades 48% above that price. The mechanical path: if the stock reverts toward the offering price, that is a 32% move. If it breaks below $7.41, the 1-month low at $5.16 becomes the next gravitational point, a 53% move from current levels. Upside risk: if retail momentum or a biotech sector rally pushes ABSI above $13, that is a 19% move against the short. The volatility is the setup.
What should surprise the reader: Eli Lilly bought $40M of stock at $7.41. The market read this as a clinical endorsement. It is not. Lilly's $40M allocation is a strategic investment in a collaboration partner, not a clinical validation. The HEADLINE trial has not produced a single efficacy data point. No hair count, no target area measurements, no patient-reported outcomes. The "positive" data is that 32 healthy volunteers did not experience serious adverse events. This is the minimum bar for any Phase 1 trial. The market has priced it as if Lilly underwrote the clinical outcome.
The Setup
Absci Corporation is a clinical-stage biopharmaceutical company using generative AI to design antibody therapeutics. Its lead candidate, ABS-201, targets the prolactin receptor (PRLR) for androgenetic alopecia (pattern hair loss) and endometriosis. The company went public via SPAC merger in 2021 at $10/share. The stock traded as low as $1.50 in early 2024 and $2.24 as recently as January 2026.
On June 24, 2026, Absci did two things simultaneously: it priced a $100M follow-on offering of 13.5M shares at $7.41 per share, and it released interim Phase 1 safety data from the HEADLINE trial. The stock closed at $10.07 that day, up 36% from $7.41, and has since drifted to $10.95.
The Market Price
| Metric | Value | Source |
|---|---|---|
| Closing price (June 26, 2026) | $10.95 | Yahoo Finance chart API |
| 6-month range | $2.24 - $11.36 | Yahoo Finance 6-month chart |
| 1-month range | $5.16 - $10.98 | Yahoo Finance 1-month chart |
| Offering price (June 24, 2026) | $7.41 | 424B5 prospectus supplement |
| Underwriter purchase price | $6.9654 | 8-K Exhibit 1.1 underwriting agreement |
| 20-day average volume | 7,848,584 | Yahoo Finance 20-day data |
| June 24 volume | 38,227,100 | Yahoo Finance daily data |
| Post-offering shares outstanding | 168,845,412 | 424B5 prospectus supplement |
| Fully diluted shares (incl. options, RSUs, plan) | ~213,500,000 | 424B5 prospectus supplement |
| Market cap at $10.95 (post-offering) | ~$1,849M | Calculated |
| Fully diluted market cap at $10.95 | ~$2,338M | Calculated |
| Shelf registration | $400,000,000 | S-3 base prospectus |
The stock trades at $10.95. Four investment banks priced 13.5M shares at $7.41 two days ago. The underwriters paid $6.97 per share. The stock is 48% above the public offering price and 57% above the underwriter cost basis.
The Positioning
The positioning is defined by three forces pulling in opposite directions.
Retail momentum: The stock surged from $5.16 to $10.95 in one month, a 112% rally. Volume on June 24 hit 38.2M shares, 4.9x the 20-day average of 7.8M. This is momentum-driven buying, not fundamental accumulation. The buyer profile is retail and momentum funds responding to the "Lilly-backed" headline and the "AI biotech" narrative.
Institutional overhang from the offering: 13.5M shares were just placed at $7.41 by Jefferies, JP Morgan, TD Securities, and Guggenheim. These shares are now in the hands of institutional accounts that subscribed at $7.41. The stock at $10.95 gives those accounts a 48% unrealized gain in two days. The incentive to take profit is immediate. Eli Lilly's $40M allocation (5.4M shares at $7.41) is a strategic stake, not a trading position, but the remaining $60M of placed stock is a profit-taking overhang.
The $400M shelf: Absci has a $400M S-3 shelf registration. The June 24 offering used approximately $100M of that capacity. Another $300M remains pre-registered. The company burned $26.3M in operating cash flow in Q1 2026. Post-offering cash plus marketable securities is approximately $219M, giving roughly 8 quarters of runway at current burn. But R&D spend is scaling ($19.3M in Q1 2026 vs. $16.4M in Q1 2025), and the Phase 2 endometriosis trial is expected to initiate later this year. The shelf is the mechanism for future dilution. If the stock stays above $7.41, the company has every incentive to sell more stock.
Short interest data was unavailable through Yahoo Finance. This is a missing-data note. Given the 38M-share volume on June 24 and the 7.8M 20-day average, the float turnover suggests high retail participation. Short interest may be moderate, but squeeze risk cannot be excluded without verified data.
The Catalyst
Immediate (days): The 13.5M shares placed at $7.41 are settleable and tradeable. Institutional accounts sitting on a 48% two-day gain have a mechanical incentive to monetize. The offering closed June 24. Settlement was T+1 (June 25). The shares are now free-trading.
Near-term (weeks): The $400M shelf has $300M remaining capacity. If the stock holds above $7.41, Absci can file another prospectus supplement and sell more stock. The company's stated use of proceeds is funding ABS-201 development. The Phase 2 endometriosis trial initiation is expected "later this year." Each of these milestones requires capital. The shelf is the capital mechanism.
Medium-term (H2 2026): Interim proof-of-concept data from the HEADLINE trial is expected in the second half of 2026. This is the binary catalyst. If the PoC data shows hair regrowth in the MAD cohorts, the stock could re-rate substantially higher. If the data is disappointing, the stock could collapse. The short thesis does not require the PoC data to fail. It requires the stock to revert from $10.95 toward the $7.41 offering price before the PoC data arrives, because the $7.41 price was set by four underwriters with full access to the company's data, financials, and pipeline.
The reflexivity: If the stock declines toward $7.41, the company's ability to raise capital at favorable prices diminishes. If ABSI needs to sell stock below $7.41, the dilution per dollar raised increases, which further pressures the stock. This is the reflexive downside: lower price equals more dilution equals lower price.
The Gap
The market is pricing ABSI as an AI-biotech company with Lilly validation and a Phase 1 success.
The filings describe a company with $215,000 in Q1 2026 contract revenue, $30.8M in quarterly operating losses, $26.3M in quarterly cash burn, a $400M dilution shelf, and a Phase 1 trial that has produced safety data only. The "positive" interim data is that 32 healthy volunteers tolerated the drug without serious adverse events. This is the baseline expectation for any Phase 1 trial. It is not efficacy.
The gap between $10.95 and $7.41 is the gap between what the market believes (Lilly validated the science, AI biotech is the future, the Phase 1 data is meaningful) and what the filings describe (a pre-revenue biotech that just sold 13.5M shares at $7.41 to fund operations, with no efficacy data for months).
The Payoff Map
The payoff is path-dependent. The key variable is whether the stock reverts toward the offering price before the PoC data arrives in H2 2026.
Top case (for the short): Institutional selling from the $7.41 placement overhang plus retail momentum exhaustion drives the stock back toward $7.41 within 2-4 weeks. The 48% premium collapses. If the stock breaks below $7.41, the 1-month low at $5.16 becomes the next target. Downside from $10.95: 32% to $7.41, 53% to $5.16.
Base case: Gradual reversion toward $8.00-$8.50 as the initial excitement fades and institutional accounts take profit. The stock stabilizes above the offering price but well below current levels, as the market waits for PoC data. Downside from $10.95: 22-27%.
Bottom case (for the short): The PoC data in H2 2026 shows meaningful hair regrowth, or Lilly expands its collaboration, or a biotech sector rally sustains momentum above $13. The stock could run to $15-$20, creating 37-83% upside risk for the short. This is the binary risk that makes position sizing critical.
Price Target and Probability Map
| Scenario | Price Target | Probability | Rationale |
|---|---|---|---|
| Top case (short) | $5.16 | 20% | Full reversion to 1-month low; institutional selling + shelf deployment; pre-PoC exhaustion |
| Base case (short) | $7.41 | 45% | Reversion to offering price set by underwriters; profit-taking from placement accounts; 2-4 week window |
| Bottom case (short) | $13.00 | 25% | Momentum sustains; biotech sector bid; Lilly collaboration expansion rumor; partial squeeze |
| Extreme upside (short risk) | $18.00 | 10% | Positive PoC data leaked early; FDA fast-track designation; major partnership announcement |
Probability-weighted expected value for a short initiated at $10.95:
(0.20 x $5.16) + (0.45 x $7.41) + (0.25 x $13.00) + (0.10 x $18.00) = $1.03 + $3.33 + $3.25 + $1.80 = $9.41
Expected value: $9.41, implying 14% downside from $10.95. The asymmetry is moderate, not extreme. The base case (45%) captures the mechanical reversion to the offering price. The tail risk (35% combined for $13 and $18) is the biotech binary that requires disciplined position sizing.
What Could Go Wrong
The strongest counterargument is that the offering price is not a ceiling. Biotech stocks routinely trade above their offering prices when the use of proceeds funds a credible clinical program. Lilly's $40M participation is a genuine signal: Lilly has a capital allocation process, and $40M is not token. If Lilly's internal diligence concluded that ABS-201 has promise, the $7.41 price may reflect a negotiated discount to fair value, not a fundamental ceiling. Biotech offerings are typically priced at a discount to induce participation, and a 36% pop on the offering day is unusual but not unprecedented for a company with a novel mechanism and a large addressable market (80M Americans with androgenetic alopecia).
The second risk is the binary catalyst. Proof-of-concept data in H2 2026 could transform the fundamentals. If the MAD cohorts show target area hair count improvement, the stock could re-rate to $20-$30, making any short entered at $10.95 catastrophically wrong. This is not a gradual-decline thesis. It is a timing thesis: the stock is ahead of its evidence, and the evidence will not arrive for months.
The third risk is short squeeze. With 38M shares traded on June 24 and a 7.8M 20-day average, the volume profile suggests high retail participation. If short interest builds and retail buying continues, a squeeze above $13 is possible. Short interest data was unavailable; this is a missing-data note.
What Would Prove This Wrong
- The stock holds above $10 for 10+ trading days without meaningful volume decline, suggesting the $7.41 offering price is not a gravitational anchor.
- Absci announces a major partnership expansion with Lilly that includes upfront payments, milestone payments, or equity investment above the $40M already committed.
- The FDA grants ABS-201 a fast-track or breakthrough therapy designation, which would re-rate the clinical risk profile.
- Interim PoC data from the MAD cohorts is released early and shows statistically significant hair regrowth.
- The company files a second offering above $7.41, demonstrating that the market, not the underwriters, is setting the price.
Risk Audit
Strongest counterargument: The $7.41 offering price is a negotiated discount, not a fundamental ceiling. Biotech follow-ons typically price below market to clear the book. The 36% pop reflects genuine demand, not irrational exuberance. Lilly's $40M is real diligence money from a sophisticated pharma buyer.
Most fragile assumption: That the offering price functions as a ceiling. This assumes institutional placement accounts will take profit. If they are long-only funds with multi-quarter holding periods, the selling pressure may not materialize. The 48% premium could persist if the float is absorbed by buy-and-hold accounts.
What the market may already know: The offering price, the Lilly participation, and the Phase 1 safety data are all public. The short thesis is not based on hidden information. It is based on the market overweighting the Lilly halo and underweighting the financials.
What could make the trade lose money even if the thesis is directionally right: The stock reverts to $7.41 but the short was stopped out at $13 during a momentum spike. Path dependency matters more than endpoint for shorts.
Liquidity / execution risks: ABSI is liquid (7.8M 20-day average volume, 38M on June 24). Borrow availability is unknown. Put options may be available but implied volatility is likely elevated post-offering. Insufficient live data on borrow cost and options chain.
Leverage risks: Shorting biotech stocks with pending binary catalysts is inherently leveraged. A gap up on PoC data or partnership news can produce 30-50% overnight moves against the position.
Information reliability risks: All financial data is from SEC filings (10-Q, 424B5, 8-K, S-3) and XBRL companyfacts. Price data is from Yahoo Finance. Short interest and borrow data are missing.
Invalidation trigger: Close above $13 for 3 consecutive sessions, or a partnership/Lilly expansion announcement, or FDA fast-track designation. Any of these would shift the thesis from "offering price reversion" to "fundamental re-rating" and the short should be closed.
Publish / revise / reject recommendation: Publish. The setup is fresh (2-day-old offering), the filing evidence is strong, and the gap between $10.95 and $7.41 is large. The binary catalyst risk is real but manageable with position sizing and invalidation triggers.
Best Trade Strategy
| Field | Value |
|---|---|
| Direction | Short |
| Preferred instrument | Common stock short, staged over 2-3 sessions |
| Common-stock stance | Short ABSI with staged entry: 50% at current levels ($10.50-$11.00), 50% on a rally toward $11.50-$12.00. Avoid shorting into intraday lows below $9.50. |
| Options stance | Insufficient live data on options chain. If put options are available, OTM puts at $8 or $7.50 strike with 30-60 DTE may cap downside risk. Check bid-ask spread before executing. |
| Entry reference | $10.50-$11.00 for first tranche; $11.50-$12.00 for second tranche |
| Take-profit | $7.41 (offering price) for 50% of position; $6.00 for remaining 50% |
| Stop-loss / invalidation | Close above $13.00 for 2 consecutive sessions. Hard stop at $13.50. |
| Time horizon | 2-6 weeks. Exit before interim PoC data expected in H2 2026. |
| Execution risks | Squeeze risk from high volume and retail participation. Borrow availability unknown. Gap risk if partnership news breaks. |
| Do-not-trade conditions | Do not short if borrow cost exceeds 20% annualized. Do not short if FDA grants ABS-201 fast-track or breakthrough designation. Do not short if Lilly announces expanded collaboration. Do not add to position below $8.00 (offering price reversion achieved). |
| Monitoring checklist | 1. Daily price vs $7.41 offering price. 2. Volume trend (declining volume = momentum exhausting). 3. Any new S-3 or 424B5 filing (additional offering = bearish). 4. Any 8-K with partnership, FDA, or clinical trial updates. 5. Short interest if available. 6. Sector biotech ETF (XBI, IBB) direction. |
| Sourced live prices | ABSI close $10.95 on June 26, 2026 (Yahoo Finance chart API). 6-month range $2.24-$11.36. 1-month range $5.16-$10.98. 20-day avg volume 7,848,584. June 24 volume 38,227,100. Offering price $7.41 (424B5 filed June 24, 2026). |
Bottom Line
Absci at $10.95 is a $1.85B market cap company with $215,000 in quarterly revenue. Four investment banks priced its stock at $7.41 two days ago. Eli Lilly bought $40M at that price. The market has since bid the stock 48% above the offering, pricing a Lilly halo and a Phase 1 safety readout as if they were clinical validation. They are not. The HEADLINE trial has not produced a single efficacy data point. The proof-of-concept data is months away. The $400M shelf has $300M remaining. The mechanical path is reversion toward $7.41, the price set by the most informed sellers in the market. The binary risk is that the PoC data shows hair growth and the stock doubles. That risk is real. It is why position sizing matters. The short is a timing trade, not a fundamental verdict on ABS-201.
Research Quality Scorecard
| Criterion | Score 1 | Score 3 | Score 5 | Rating |
|---|---|---|---|---|
| Market disagreement | Vague price story | Plausible disagreement | Clear price-positioning-catalyst tension | 5 |
| Evidence base | Weak or stale | Mixed but usable | Fresh primary or market data | 5 |
| Positioning and flows | Missing | Partly supported | Non-obvious and well evidenced | 3 |
| Catalyst path | No clear trigger | Soft or uncertain trigger | Observable catalyst or reflexive mechanism | 5 |
| Payoff architecture | Unclear | Moderately skewed | Clearly asymmetric with defined downside | 4 |
| Invalidation discipline | Missing | Partly testable | Explicit, monitorable thesis break | 5 |
| Differentiated insight | Consensus view | Some differentiation | Non-obvious and defensible | 4 |
| Client value | Interesting only | Some decision value | Useful even if no trade is taken | 5 |
Total: 36/40. Publish-ready Deep Dive. The positioning score is 3 due to missing live short interest and borrow data, which prevents a 5. The payoff score is 4 due to the binary biotech catalyst creating meaningful tail risk that limits the asymmetry from a pure 5.
Sources
| Source | Type | Date Accessed |
|---|---|---|
| ABSI 424B5 prospectus supplement (Filed June 24, 2026) | SEC primary filing | June 27, 2026 |
| ABSI 8-K (Underwriting agreement, June 24, 2026) | SEC primary filing | June 27, 2026 |
| ABSI 8-K Exhibit 99.1 (Phase 1 interim data press release, June 24, 2026) | SEC primary filing | June 27, 2026 |
| ABSI 10-Q for quarter ended March 31, 2026 (Filed May 7, 2026) | SEC primary filing | June 27, 2026 |
| ABSI S-3 base prospectus ($400M shelf, Registration No. 333-289541) | SEC primary filing | June 27, 2026 |
| ABSI XBRL companyfacts (CIK 0001672688) | SEC structured data | June 27, 2026 |
| ABSI Form 4 filings (June 2026) | SEC primary filing | June 27, 2026 |
| Yahoo Finance chart API (ABSI price and volume data) | Market data | June 27, 2026 |
| MVIS 424B5 prospectus (Filed June 24, 2026) | SEC primary filing | June 27, 2026 |
| MVIS XBRL companyfacts (CIK 0000065770) | SEC structured data | June 27, 2026 |
| NXTS XBRL companyfacts (CIK 0001789192) | SEC structured data | June 27, 2026 |
| Yahoo Finance (MVIS, NXTS, TOYO, FIEE, LGCL price data) | Market data | June 27, 2026 |
| SEC EDGAR full-text search (efts.sec.gov) | SEC search tool | June 27, 2026 |
Illustration Prompt
A high-end editorial illustration for a financial research publication. The scene depicts a gleaming pharmaceutical halo made of golden light hovering above a small, fragile clinical vial labeled with a barcode. The vial sits on a weighing scale tilted sharply to one side, with a towering stack of dollar coins on the heavy side and a single tiny revenue receipt on the light side. The background is a dark, clinical laboratory setting with blurred data screens showing falling red candlestick charts. The mood is tension between clinical hope and financial gravity. Color palette: deep navy, clinical white, gold halo, crimson accent. Composition: centered, dramatic lighting from above, shallow depth of field. Style: realistic, high-value, as if commissioned for the cover of Barron's or a Bloomberg Markets feature. Includes a subtle but clear watermark reading "The Mispricing Desk" in the lower right corner. No generic stock-photo language. No text other than the watermark.